{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:36:38Z","timestamp":1768282598434,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T00:00:00Z","timestamp":1509926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00198-017-4271-1","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T07:14:39Z","timestamp":1509952479000},"page":"329-337","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study"],"prefix":"10.1007","volume":"29","author":[{"given":"A.","family":"Modi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mellstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. P.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Keown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sajjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,6]]},"reference":[{"key":"4271_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1210\/jc.2007-1876","volume":"93","author":"JS Finkelstein","year":"2008","unstructured":"Finkelstein JS, Brockwell SE, Mehta V et al (2008) Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 93:861\u2013868","journal-title":"J Clin Endocrinol Metab"},{"key":"4271_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"4271_CR3","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1016\/j.clinthera.2008.12.019","volume":"30","author":"FE Cotte","year":"2008","unstructured":"Cotte FE, Mercier F, De Pouvourville G (2008) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 30:2410\u20132422","journal-title":"Clin Ther"},{"key":"4271_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1185\/030079906X167615","volume":"23","author":"DT Gold","year":"2007","unstructured":"Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin 23:585\u2013594","journal-title":"Curr Med Res Opin"},{"key":"4271_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proc 81:1013\u20131022","journal-title":"Mayo Clinic Proc"},{"key":"4271_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/IJGM.S36944","volume":"6","author":"A Balasubramanian","year":"2013","unstructured":"Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839\u2013848","journal-title":"Int J Gen Med"},{"key":"4271_CR7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1359\/jbmr.080510","volume":"23","author":"AM Gallagher","year":"2008","unstructured":"Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569\u20131575","journal-title":"J Bone Miner Res"},{"key":"4271_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"4271_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s00198-006-0085-2","volume":"17","author":"JC Lo","year":"2006","unstructured":"Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922\u2013928","journal-title":"Osteoporos Int"},{"key":"4271_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2008.12.001","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES (2009) Clinical issues with bisphosphonate therapy for osteoporosis. Introduction. Am J Med 122:S1\u2013S2","journal-title":"Am J Med"},{"key":"4271_CR11","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1185\/030079906X132370","volume":"22","author":"CH Boogaard van den","year":"2006","unstructured":"van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM (2006) Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757\u20131764","journal-title":"Curr Med Res Opin"},{"key":"4271_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.5414\/CP201632","volume":"50","author":"V Ziller","year":"2012","unstructured":"Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P (2012) Persistence and compliance of medications used in the treatment of osteoporosis\u2014analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 50:315\u2013322","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4271_CR13","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.clinthera.2006.10.013","volume":"28","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W (2006) The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686\u20131694","journal-title":"Clin Ther"},{"key":"4271_CR14","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.bone.2011.12.021","volume":"50","author":"SW Wade","year":"2012","unstructured":"Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870\u2013875","journal-title":"Bone"},{"key":"4271_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bone.2007.07.009","volume":"41","author":"BA Briesacher","year":"2007","unstructured":"Briesacher BA, Andrade SE, Yood RA, Kahler KH (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882\u2013887","journal-title":"Bone"},{"key":"4271_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1007\/s00198-006-0166-2","volume":"17","author":"AJ Carr","year":"2006","unstructured":"Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638\u20131644","journal-title":"Osteoporos Int"},{"key":"4271_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1369-7625.2010.00619.x","volume":"14","author":"CA McHorney","year":"2011","unstructured":"McHorney CA, Spain CV (2011) Frequency of and reasons for medication non-fulfillment and non-persistence among American adults with chronic disease in 2008. Health Expect 14:307\u2013320","journal-title":"Health Expect"},{"key":"4271_CR18","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00198-009-1133-5","volume":"21","author":"AN Tosteson","year":"2010","unstructured":"Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW (2010) Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int 21:1769\u20131780","journal-title":"Osteoporos Int"},{"key":"4271_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1345\/aph.1Q652","volume":"46","author":"K Reynolds","year":"2012","unstructured":"Reynolds K, Viswanathan HN, O\u2019Malley CD et al (2012) Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates. Ann Pharmacother 46:659\u2013670","journal-title":"Ann Pharmacother"},{"key":"4271_CR20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1185\/03007991003633603","volume":"26","author":"C Woo","year":"2010","unstructured":"Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003\u20131009","journal-title":"Curr Med Res Opin"},{"key":"4271_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2474-15-112","volume":"15","author":"H Yun","year":"2014","unstructured":"Yun H, Curtis JR, Guo L et al (2014) Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord 15:112","journal-title":"BMC Musculoskelet Disord"},{"key":"4271_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0149-2918(04)90023-9","volume":"26","author":"C Turbi","year":"2004","unstructured":"Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R, Sacristan J, Marin F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245\u2013256","journal-title":"Clin Ther"},{"key":"4271_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00198-015-3388-3","volume":"27","author":"A Modi","year":"2016","unstructured":"Modi A, Sen S, Adachi JD et al (2016) Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27:1227\u20131238","journal-title":"Osteoporos Int"},{"key":"4271_CR24","first-page":"537","volume":"33","author":"A Modi","year":"2015","unstructured":"Modi A, Sen S, Adachi JD et al (2015) Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada. Clin Exp Rheumatol 33:537\u2013544","journal-title":"Clin Exp Rheumatol"},{"key":"4271_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00198-011-1555-8","volume":"23","author":"V Breuil","year":"2012","unstructured":"Breuil V, Cortet B, Cotte FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, Roborel de Climens A, Legrand E (2012) Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 23:445\u2013455","journal-title":"Osteoporos Int"},{"key":"4271_CR26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","volume":"28","author":"FJ Penning-van Beest","year":"2006","unstructured":"Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236\u2013242","journal-title":"Clin Ther"},{"key":"4271_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","volume":"17","author":"M Rossini","year":"2006","unstructured":"Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice Study G (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914\u2013921","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4271-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4271-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4271-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T01:28:45Z","timestamp":1554341325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4271-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,6]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4271"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4271-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,6]]},"assertion":[{"value":"22 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and either the local ethics board or a central institutional review board. All participants provided written informed consent prior to enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A. Modi and S. Sen are employees of Merck & Co., Inc. and own stock in the company. J.D. Adachi has received grant support and speaker honorarium from Actavis, Amgen, Eli Lilly, Merck & Co., Inc. and Novartis. J.D. Adachi is a consultant for Amgen, Eli Lilly, and Merck & Co., Inc. S. Adami has received consulting honorarium from Merck & Co., Inc. and served as a board member for Merck & Co., Inc. B. Cortet has received research grants, consulting honorarium, and\/or speaker honorarium from Amgen, Expanscience, Ferring, Eli Lilly, Merck & Co., Inc., Merck Sharp & Dohme, Medtronic, and Roche diagnostics. A.L. Cooper has received research grants, advisory board and\/or speaker honorarium from Consilient Health and Internis Pharmaceuticals. P. Geusens has received research grants, advisory board and\/or speaker honorarium from Pfizer, Abbott, Eli Lilly, Amgen, Merck Sharp & Dohme, Will Pharma, Roche, UCB pharmaceuticals, Bristol-Myers Squibb, and Novaritis. D.Mellstr\u00f6m has received consulting honorarium from Merck Sharp & Dohme. J.P. Weaver is an employee of Merck & Co., Inc. J.P. van den Bergh is a paid consultant at Amgen and Will Pharma. J.P. van den Bergh has received research grants and speaker honorarium from Amgen, Will Pharma, and Eli Lilly. P.A. Keown is the director of and employed by Syreon Corporation and has received financial remuneration from Merck & Co., Inc. to conduct the study, participate in study meetings, and perform statistical analysis. S. Sajjan was an employee of Merck & Co., Inc. and owned stock in the company at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}